BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-90189892 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-90189892\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06651229-3090@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:JNJ-90189892: Phase 1 readout est. (NCT06651229)
DESCRIPTION:JNJ-90189892\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Mye
 lodysplastic Neoplasms\nEstimated primary completion: 5 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/jnj-90189892#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06651229
URL:https://assetmemo.bio/drug/jnj-90189892#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
